Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 5 , Pages 849-868 , October 2008

Anti-resorptives in the management of osteoporosis

  • Paul D. Miller, MD (Medical Director)

      Affiliations

    • Corresponding Author InformationTel.: +1 303 980 9985; Fax: +1 303 980 1367.

References 

  1. Burr DB, Turner CH. Biomechanics of bone. In:  Favus M editors. Primer on the metabolic bone diseases and disorders of mineral metabolism. Washington, DC: American Society for Bone and Mineral Research; 2003;p. 58–64
  2. Heaney R. Remodeling and skeletal fragility. Osteoporosis International. 2003;14(S 5):S12–S15
  3. Pivonka P, Zimak J, Smith DW, et al. Model structure and control of bone remodeling: a theoretical study. Bone. 2008;43(2):249–263
  4. Huang JC, Sakata T, Pfleger LL, et al. PTH differentially regulates expression of RANKL and OPG. Journal of Bone and Mineral Research. 2004;19(4):235–244
  5. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–342
  6. Bekker PJ, Holloway DL, Rasmussen AS, et al. Single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. Journal of Bone and Mineral Research. 2004;19(7):1059–1066
  7. Bonewald LF, Johnson ML. Osteocytes, mechanosensing, and Wnt signaling. Bone. 2008;42(4):606–615
  8. Bonewald LF. Osteocytes: a proposed multifunctional bone cell. Journal of Musculoskeletal & Neuronal Interactions. 2002;2(3):239–241
  9. Piters E, Boudin E, Van Hul W. Wnt signaling: a win for bone. Archives of Biochemistry and Biophysics. 2008;473(2):112–116
  10. Ten Dijke P, Krause C, de Gorter DJ, et al. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. The Journal of Bone and Joint Surgery. 2008;90(1):31–35
  11. Duque G. Bone and fat connection in aging bone. Current Opinion in Rheumatology. 2008;20(4):429–434
  12. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone?. Nature Clinical Practice Rheumatology. 2006;2(1):35–43
  13. Davison KS, Siminoski K, Adachi JD, et al. The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future. Seminars in Arthritis and Rheumatism. 2006;36(1):10–21
  14. Miller PD. The treatment of osteoporosis: anti-resorptive therapy. In:  Rosen) Clifford editors. Clinics in laboratory medicine. Philadelphia, PA: W.B. Saunders Co.; 2000;p. 603–622
  15. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. The Journal of the American Medical Association. 2002;288(3):321–333
  16. Jackson RD, Shidham S. The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: lessons learned from the Women's Health Initiative. Current Osteoporosis Reports. 2007;5(4):153–159
  17. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. The Journal of the American Medical Association. 2003 Oct 1;290(13):1729–1738
  18. Lindsay R. Hormones and bone health in postmenopausal women. Endocrine. 2004;24(3):223–230
  19. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American menopause society. Menopause. 2008;15(4):584–602
  20. Kirahnan V, Heath H, Bryant HU. Mechanism of action of estrogens and selective estrogen receptor modulators. Vitamins and Hormones. 2000;60:123–147
  21. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. The Journal of the American Medical Association. 1999;282(7):637–645
  22. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. Journal of Bone and Mineral Research. 2008;4:525–535
  23. Bevers R. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. Journal of the National Comprehensive Cancer Network. 2007;5(8):719–724
  24. Jordan VC. The rise of raloxifene and the fall of invasive breast cancer. Journal of the National Cancer Institute. 2008 Jun 18;100(12):831–833
  25. Notelovitz M. Postmenopausal tibolone therapy: biologic principles and applied clinical practice. Medscape General Medicine. 2007 Jan 3;9(1):2
  26. Prelevic GM, Markou A, Arnold A, et al. The effect of tibolone on bone mineral density in postmenopausal women with osteopenia or osteoporosis – 8 years follow-up. Maturitas. 2004;47(3):229–234
  27. Ettinger B. Tibolone for the prevention and treatment of postmenopausal osteoporosis. Maturitus. 2007 May 20;57(1):35–38
  28. Delmas PD, Davis SR, Hensen J, et al. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Osteoporosis International. 2008;
  29. Karsdal MA, Henriksen K, Arnold M, et al. Calcitonin – a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. Biodrugs. 2008;22(3):137–144
  30. Body JJ. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone. 2002;30(5):75S–79S
  31. Siminoski K, Josse RG. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis. Canadian Medical Association Journal. 1996;155(7):962–965
  32. Chesnut CH, Silverman S, Andriano K, et al. Randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. The American Journal of Medicine. 2000;109(4):267–276
  33. Chesnut CH, Majumdar S, Newitt DC, et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. Journal of Bone and Mineral Research. 2005;20(9):1548–1561
  34. Chesnut CH, Azria M, Silverman S, et al. Salmon calcitonin: a review of current and future therapeutic indications. Osteoporosis International. 2008;19(4):479–491
  35. Fleisch H, Russell RG, Francis D. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969;165:1262–1264
  36. Russell RG, Muhlbauer Rc S, Bisaz D, et al. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapetite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomized rats. Calcified Tissue Research. 1970;6:183–189
  37. Russell RGG, Rogers M. Bisphosphonates: from the laboratory to the clinic and back again. Bone. 1999;25:97–106
  38. Rogers M. New insights into the molecular mechanisms of action of bisphosphonates. Current Pharmaceutical Design. 2003;9:2643–2658
  39. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapetite. Bone. 2006;38:617–627
  40. Plotkin LI, Manolagas SC, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone. 2006;39:443–452
  41. Russell RGG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis International. 2008;19:733–759
  42. Miller PD. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In:  Marcus R,  Feldman D,  Nelson DA,  Rosen CJ editor. Osteoporosis. 3rd ed.. San Diego, CA: Elsevier Academic Press; 2007;p. 1725–1736
  43. Papapoulos S. Who will benefit from anti-resorptive treatment (bisphosphonates)?. Best Practice & Research. Clinical Rheumatology. 2005;19(6):965–973
  44. Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clinical Therapeutics. 2005;27(4):1–16
  45. Miller PD. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Current Osteoporosis Reports. 2005;3(3):103–110
  46. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. The New England Journal of Medicine. 2007;356(18):1809–1822
  47. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. The New England Journal of Medicine. 1990;323(2):73–79
  48. Kleerekoper M, Peterson EL, Nelson D, et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis International. 1991;1(3):155–161
  49. van Staa TP, Abenhaim L, Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. British Journal of Rheumatology. 1998;37(1):87–94
  50. Storm T, Steiniche T, Thamsborg G, et al. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. Journal of Bone and Mineral Research. 1993;8(2):199–208
  51. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1998;348:1535–1541
  52. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. The Journal of the American Medical Association. 1998;280:2077–2082
  53. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporosis International. 1999;9(5):461–468
  54. Bonnick SL, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. The Journal of Clinical Endocrinology and Metabolism. 2006;91(7):2631–2637
  55. Miller PD, Hochberg MC, Wehren LE, et al. How useful are measures of BMD and bone turnover?. Current Medical Research and Opinion. 2005;21(4):545–554
  56. Miller PD. Monitoring osteoporosis therapies. Current Osteoporosis Reports. 2007;5:38–43
  57. Wasnich RD, Miller PD. Antifracture efficacy of antiresportive agents are related to changes in bone density. Clinics in Endocrinology and Metabolism. 2000;85:1–6
  58. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs. The American Journal of Medicine. 2002;112:281–289
  59. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. The American Journal of Medicine. 2006;119(4 Suppl. 1):S25–S31
  60. Watts NB, Geusens P, Barton IP, et al. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. Journal of Bone and Mineral Research. 2005;20(12):2097–2104
  61. Seeman E. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?. Bone. 2007;41(3):308–317
  62. Borah B, Dufresne TE, Chmielewski PA, et al. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. Journal of Bone and Mineral Research. 2002;17(7):1139–1147
  63. Borah B, Dufresne TE, Ritman TL, et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone. 2006;39(2):345–352
  64. Bauss F, Dempster DW. Effects of ibandronate on bone quality: preclinical studies. Bone. 2007;40(2):265–273
  65. Seeman E, Delmas PD. Bone quality – the material and structural basis of bone strength and fragility. The New England Journal of Medicine. 2006 May 25;354(21):2250–2261
  66. Seeman E. Bone quality: the material and structural basis of bone strength. Journal of Bone and Mineral Metabolism. 2008;26(1):1–8
  67. Lewiecki EM, Watts NB. Assessing response to osteoporosis therapy. Osteoporosis International (in press).
  68. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term extension (FLEX): a randomized trial. The Journal of the American Medical Association. 2006;296(24):2927–2938
  69. Curtis JR, Westfall AO, Cheng H, et al. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporosis International (in press).
  70. Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporosis International. 2008;19(3):365–372
  71. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. The Journal of the American Medical Association. 1999;282:1344–1352
  72. Reginster J-Y, Minne H, Sorenson OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis International. 2000;11:83–91
  73. Sorenson OH, Crawford GM, Mulder H, et al. Long term efficacy of risedronate: a 5 year clinical experience. Bone. 2003;32:120–126
  74. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The New England Journal of Medicine. 1995;333:1437–1443
  75. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Journal of Bone and Mineral Research. 2004;19:1241–1249
  76. Silverman SL, Watts NB, Delmas PD, et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporosis International. 2007;18(1):25–34
  77. McClung MR, Geusens P, Miller PD, et al. The effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. The New England Journal of Medicine. 2001;344:333–340
  78. Delmas PD, Benhamou CL, Man C, et al. Monthly dosing of 75mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporosis International. 2008;19(7):1039–1045
  79. Siris E, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clinic Proceedings. Mayo Clinic. 2006 Aug;81(8):1013–1022
  80. Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: one year results from the MOBILE study. Journal of Bone and Mineral Research. 2005;20:1315–1322
  81. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal osteoporosis: 1-year results from the dosing intravenous administration (DIVA) study. Arthritis and Rheumatism. 2006;54(6):1838–1846
  82. Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone. 2004;34:881–889
  83. Miller PD. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data. Current Medical Research and Opinion. 2008;24(1):107–119
  84. Boonen S, Laan RF, Barton IP, et al. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporosis International. 2005;16(10):1291–1298
  85. Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooted analysis of individual patient data. Osteoporosis Int 2008; (in press).
  86. Harris ST, Blumenthals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Current Medical Research and Opinion. 2008;24(1):237–245
  87. Miller PD, Epstein S, Sedarati F, et al. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Current Medical Research and Opinion. 2008;24(1):207–213
  88. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. The New England Journal of Medicine. 2002 28;346(9):653–661
  89. Bolland MJ, Grey AB, Horne AM, et al. The effects of intravenous zoledronate on bone turnover and bone density persist for at least 24 months. Journal of Bone and Mineral Research. 2008;
  90. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. The New England Journal of Medicine. 2007;357:1799–1809
  91. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. The New England Journal of Medicine. 2006;354(8):821–831
  92. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. Journal of Bone and Mineral Research. 2007;22(12):1832–1841
  93. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–229
  94. Frost H. Bone's mechanostat: a 2003 update. The Anatomical Record. Part A, Discoveries in Molecular, Cellular, and Evolutionary Biology. 2003;275(2):1081–1101
  95. Genant HK, Engelke K, Brown JP, et al. Denosumab improves forearm densitometric, geometric and strength indices as measured by QCT in postmenopausal women with low BMD. European Calcified Tissue (in press).
  96. Yates J, Barrett-Conner E, Barlas S, et al. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstetrics and Gynecology. 2004;103(3):440–446
  97. Neviaser AS, Lane JM, Lenart BA, et al. Low-energy femoral shaft fractures associated with alendronate use. Journal of Orthopaedic Trauma. 2008;22(5):346–350
  98. Chapurlat RD, Arlot M, Burt-Pichat B, et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. Journal of Bone and Mineral Research. 2007;22(10):1502–1509
  99. Chavassieux P, Seeman E, Delmas PD. Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocrine Reviews. 2007;28(2):151–164
  100. Ruggiero SI, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with use of bisphosphonates: a review of 63 cases. Journal of Oral and Maxillofacial Surgery. 2004;62:527–534
  101. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone And Mineral Research. Journal of Bone and Mineral Research. 2007;22(10):1479–1491
  102. Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008;42(5):841–847
  103. Sorenson HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ (Clinical Research Ed.). 2008 12;336(7648):813–816
  104. Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. Archives of Internal Medicine. 2008;168(8):826–831
  105. Miller PD. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Current Osteoporosis Reports. 2005;3:5–12
  106. Miller PD, Roux C, Boonen S, et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault Method: a pooled analysis of nine clinical trials. Journal of Bone and Mineral Research. 2005;20:2105–2115
  107. Jamal SA, Bauer DC, Ensrud KE, et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone and Mineral Research. 2007;22:503–508
  108. Miller PD. Is there a role for bisphosphonates in patients with stage 5 chronic kidney disease?. Seminars in Dialysis. 2007;20:191–197
  109. Miller PD. The role of bone biopsy in chronic renal failure. Clinical Journal of the American Society of Nephrology (in press).
  110. Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney International (in press).
  111. Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opinion on Drug Safety. 2007;6(6):663–672
  112. Black DM, Boonen S, Delmas P, et al. Review of comparative effectiveness of treatments to prevent fractures. Annals of Internal Medicine. 2008;148(11):197–213
  113. Hosking DJ, Geusens P, Rizzoli R. Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice. QJM: Monthly Journal of the Association of Physicians. 2005;98(6):403–413
  114. Delmas PD, Rizzoli R, Cooper C, et al. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the international osteoporosis foundation. Osteoporosis International. 2005;16(1):1–5

PII: S1521-690X(08)00082-1

doi: 10.1016/j.beem.2008.07.004

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 5 , Pages 849-868 , October 2008

Article Tools